Sitamepo Tablet 50/850 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Youngil Pharmaceutical Co., Ltd.
MFDS item code 202200199 · Approved 2022.01.11
Improvement of glycemic control in type 2 diabetes mellitus
This medication helps patients with type 2 diabetes to effectively control their blood sugar levels. It is used in conjunction with dietary and exercise therapies, and is administered when previous diabetes treatments have not been effective or when blood sugar cannot be sufficiently controlled with monotherapy. Additionally, it may be used when treatment with metformin or sitagliptin alone does not adequately control blood sugar, or when it is necessary to switch from combination therapy. It can be taken alongside this medication in cases where blood sugar control is difficult even after combination therapy with metformin and sulfonylurea, or metformin and thiazolidinedione. This medication can enhance therapeutic effects when used in conjunction with insulin and metformin that are also not adequately controlling blood sugar. It is used to improve blood sugar control in various treatment scenarios.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may affect blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine).
This medication may cause serious allergic reactions at the start of treatment, so if symptoms such as skin rashes or respiratory difficulties occur, use should be discontinued immediately. Moreover, there is a risk of acute pancreatitis, which is inflammation of the pancreas, so it is essential to consult a healthcare professional promptly if symptoms such as abdominal pain or vomiting arise. Patients with impaired kidney function, heart disease, or acute infection should not use this medication, particularly if renal function is below 45 mL/min, it is forbidden to administer. Before and after using iodine contrast agents for tests, this medication should be temporarily discontinued and resumed only after confirming that renal function is normal. Women who are pregnant or breastfeeding should not take this medication, and safety and efficacy in children and adolescents under 18 years of age have not been established. This medication may cause hypoglycemia, so care should be taken with missed meals, irregular eating, or excessive exercise. Patients with impaired liver or kidney function, dehydration or severe infection must take special care as they may experience severe metabolic acidosis known as lactic acidosis. During treatment, it is important to regularly monitor kidney function and blood tests for any abnormalities. Excessive alcohol consumption increases the risk of side effects, so drinking should be avoided while taking this medication. If surgery is planned, use should be discontinued 48 hours prior to the procedure, and resumed only after confirming normal kidney function post-surgery. This medication may increase the risk of hypoglycemia when used with other diabetes medications, so dose adjustments may be needed according to a doctor's instructions. If skin blisters or severe joint pain develop during medication, contact healthcare professionals immediately. In the case of overdose, treatments such as blood dialysis may be necessary, so dosage must be strictly followed. When administering this medication to the elderly, dosage adjustments should be made considering declining kidney function, and regular monitoring is essential.
Anaphylaxis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture from entering and should be kept at room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain its effectiveness for a longer period.
Pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Youngil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.